Product image of Ondansetron Aristo (Ondansetron Hydrochloride Dihydrate) supplied by GNH India

Ondansetron Aristo

Active Ingredient:
Ondansetron Hydrochloride Dihydrate
Origin:
EU

Ondansetron Aristo (Ondansetron Hydrochloride Dihydrate)

Ondansetron Hydrochloride Dihydrate, the active ingredient in Ondansetron Aristo, is a 5-HT3 receptor antagonist presented as an injection for intravenous use. It is used to prevent nausea and vomiting associated with chemotherapy, radiotherapy and postoperative recovery in adult and pediatric patients.

GNH India supplies Ondansetron Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Aristo Pharma Gmbh (Art 57)

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ondansetron Aristo is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting pathways.

  • Chemotherapy‑induced nausea and vomiting: helps control the acute and delayed phases, improving patient comfort during cancer treatment.
  • Radiotherapy‑induced nausea and vomiting: reduces the frequency and severity of nausea associated with radiation sessions.
  • Post‑operative nausea and vomiting: decreases the incidence of nausea and vomiting after surgical procedures, supporting faster recovery.

How It Works

  • Ondansetron blocks the 5‑HT3 receptors located on peripheral vagal nerve terminals and within the chemoreceptor trigger zone of the brain. By competitively antagonising serotonin binding, it interrupts the neural signaling cascade that initiates nausea and vomiting, thereby providing anti‑emetic protection during emetogenic stimuli.

Side Effects

Side effects reported with ondansetron injection are generally mild to moderate and vary with individual sensitivity.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Constipation: reduced bowel motility.
  • Diarrhoea: occasional loose stools.
  • Fatigue: feeling of tiredness.
  • Dizziness: transient light‑headedness.
  • Injection site reactions: erythema or mild pain.

Serious or Rare Side Effects

  • Cardiac arrhythmia: QT‑interval prolongation, especially with rapid IV administration.
  • Severe hypersensitivity: anaphylaxis, angio‑edema, or skin rash.
  • Serotonin syndrome: rare when combined with other serotonergic agents.
  • Hepatic dysfunction: elevated liver enzymes.
  • Neuro‑muscular weakness: rare cases of muscle rigidity.
  • Pulmonary edema: very rare, usually in high‑risk patients.

Precautions & Warnings

When using Ondansetron Aristo, clinicians should consider several safety measures to minimise risk.

  • Cardiac monitoring: patients with known QT prolongation or electrolyte disturbances should be monitored.
  • Concomitant serotonergic drugs: assess risk of serotonin syndrome.
  • Renal or hepatic impairment: dose adjustment may be required.
  • Pregnancy and lactation: use only if clearly needed; benefits must outweigh the potential risk.
  • Pediatric use: weight‑based dosing is essential; follow prescriber guidance.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Ondansetron may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Apomorphine: may cause profound hypotension and loss of consciousness.
  • Certain anti‑arrhythmic agents (e.g., quinidine, amiodarone): increase risk of QT prolongation.
  • Serotonergic antidepressants (SSRIs, SNRIs, MAOIs): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inhibitors (ketoconazole, erythromycin): may raise ondansetron plasma levels.
  • CYP2D6 substrates (tramadol, codeine): potential for altered metabolism.
  • Diuretics causing electrolyte loss: may exacerbate QT‑interval effects.

Frequently Asked Questions

Ondansetron Aristo is an injectable form of ondansetron hydrochloride dihydrate used to prevent and treat nausea and vomiting that can occur after chemotherapy, radiotherapy or surgery. It is administered intravenously under medical supervision to provide rapid anti‑emetic relief in patients at risk of emetogenic triggers.

Ondansetron selectively blocks 5‑HT3 receptors on peripheral vagal nerves and in the brain’s chemoreceptor trigger zone. By preventing serotonin from binding to these receptors, it interrupts the neural pathway that signals the brain to initiate nausea and vomiting, thereby offering effective anti‑emetic protection.

The dosage of Ondansetron Aristo is determined by the prescribing clinician based on the patient’s age, weight, type of emetogenic stimulus and clinical condition. Healthcare professionals set the appropriate dose and infusion rate according to established treatment guidelines.

Safety data for ondansetron in pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used when the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult their physician, as small amounts may be excreted in milk.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Ondansetron belongs to the 5‑HT3 receptor antagonist class, offering rapid onset and specific serotonin blockade. Compared with dopamine antagonists (e.g., metoclopramide) it has fewer extrapyramidal side effects and provides superior control of chemotherapy‑induced nausea, though both classes may be used complementarily in some protocols.

Ondansetron Aristo should be stored at 2‑8 °C, protected from light, and kept in its original packaging. It must not be frozen or shaken, and any solution that has been diluted for infusion should be used within the time frame recommended by the manufacturer.

The product is given by intravenous injection or infusion, typically over a few minutes for a single dose or as a continuous infusion for prolonged anti‑emetic coverage. Administration is performed by qualified healthcare personnel in a clinical setting, following aseptic technique.

Serious risks include cardiac arrhythmias such as QT‑interval prolongation, severe hypersensitivity reactions (anaphylaxis), and rare cases of serotonin syndrome when combined with other serotonergic drugs. Patients should be monitored for ECG changes and any signs of allergic response during treatment.

Ondansetron is contraindicated in patients with known hypersensitivity to ondansetron or any component of the formulation. Caution is advised for individuals with congenital long QT syndrome, uncontrolled electrolyte imbalances, or those receiving interacting medications that markedly increase QT risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ondansetron Hydrochloride Dihydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT